79691-2
Oxipurinol [Moles/volume] in Cerebral spinal fluid
Active
Part Descriptions
LP18483-5 Oxipurinol
Oxypurinol is an inhibitor of xanthine oxidase. It is an active metabolite of allopurinol and it is cleared renally. In cases of renal disease, this metabolite will accumulate to toxic levels.
Copyright Text is available under the Creative Commons Attribution/Share-Alike License. See http://creativecommons.org/licenses/by-sa/3.0/ for details.
Source: Wikipedia, Oxypurinol
LP18483-5 Oxipurinol
Oxipurinol [alloxanthine, Oxyprim, oxypurinol] is the active metabolite of the only commercially available xanthine oxidase inhibitor, allopurinol. Oxipurinol is also a xanthine oxidase inhibitor. Oxipurinol is currently being developed by Cardiome Pharma. It is waiting for approval in the US for the treatment of allopurinol-intolerant hyperuricaemia (gout) and is in phase III trials for the treatment of congestive heart failure. Allopurinol is indicated for the treatment of symptomatic hyperuricaemia, or gout. Approximately 3-5% of patients receiving allopurinol develop intolerance to the drug. Oxipurinol was originally developed by Burroughs Wellcome (later GlaxoSmithKline), and has been available on a compassionate-use basis since 1967 for use in allopurinol-intolerant patients. The licensee company ILEX Oncology has stated that oxipurinol does not have patent protection. Oxipurinol's potential for treatment of congestive heart failure is based on the possibility that xanthine oxidase inhibitors may improve myocardial work efficiency by sensitising cardiac muscle cells to calcium ions, which are a key determinant of cardiac muscle function. This results in more efficient contraction of cardiac muscle cells, without the same increase in oxygen demand. At the second annual BioPartnering North America conference (BPN-2004) [February 2004, Vancouver, Canada], Cardiome Pharma stated that it was seeking a commercialisation partner to market and distribute oxipurinol in the US for the treatment of allopurinol-intolerant hyperuricaemia. [Drugs R D. 2004;5(3):171-5.]
Source: NCBI PubMed, PMID:15139781
Fully-Specified Name
- Component
- Oxipurinol
- Property
- SCnc
- Time
- Pt
- System
- CSF
- Scale
- Qn
- Method
Additional Names
- Short Name
- Oxipurinol CSF-sCnc
- Display Name
- Oxipurinol (CSF) [Moles/Vol]
- Consumer Name Alpha Get Info
- Oxipurinol, Spinal fluid
Basic Attributes
- Class
- DRUG/TOX
- Type
- Laboratory
- First Released
- Version 2.54
- Last Updated
- Version 2.54
- Order vs. Observation
- Observation
Member of these Panels
| LOINC | Long Common Name |
|---|---|
| 79668-0 | Purine and Pyrimidine panel - Cerebral spinal fluid |
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| es-ES | Spanish (Spain) | Oxipurinol: Synonyms: Cuantitativo |
| es-MX | Spanish (Mexico) | Oxipurinol: |
| et-EE | Estonian (Estonia) | Oksipurinool: Synonyms: Aine kontsentratsioon Juhuslik Kvantitatiivne Liikvor |
| fr-CA | French (Canada) | Oxipurinol: |
| fr-FR | French (France) | Oxipurinol: |
| fr-BE | French (Belgium) | Oxipurinol: |
| it-IT | Italian (Italy) | Ossipurinolo: Synonyms: Concentrazione di Sostanza Liquido cerebrospinale Livelli farmacologici e tossicologia Punto nel tempo (episodio) |
| nl-NL | Dutch (Netherlands) | oxipurinol: |
| ru-RU | Russian (Russian Federation) | Оксипуринол: Synonyms: Количественный Молярность; |
| tr-TR | Turkish (Turkey) | Oksipürinol: |
| zh-CN | Chinese (China) | 奥昔嘌醇: Synonyms: CSF CSF; |
Example Units
| Unit | Source |
|---|---|
| umol/L | Example UCUM Units |
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=79691-2
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright